GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fennec Pharmaceuticals Inc (TSX:FRX) » Definitions » Gross Profit

Fennec Pharmaceuticals (TSX:FRX) Gross Profit : C$26.90 Mil (TTM As of Dec. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Fennec Pharmaceuticals Gross Profit?

Fennec Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was C$12.14 Mil. Fennec Pharmaceuticals's gross profit for the trailing twelve months (TTM) ended in Dec. 2023 was C$26.90 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Fennec Pharmaceuticals's gross profit for the three months ended in Dec. 2023 was C$12.14 Mil. Fennec Pharmaceuticals's Revenue for the three months ended in Dec. 2023 was C$13.06 Mil. Therefore, Fennec Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 was 92.96%.

Fennec Pharmaceuticals had a gross margin of 92.96% for the quarter that ended in Dec. 2023 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Fennec Pharmaceuticals was 94.39%. The lowest was 94.08%. And the median was 94.24%.


Fennec Pharmaceuticals Gross Profit Historical Data

The historical data trend for Fennec Pharmaceuticals's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fennec Pharmaceuticals Gross Profit Chart

Fennec Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 0.22 - 1.97 26.82

Fennec Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.97 2.17 4.22 8.37 12.14

Competitive Comparison of Fennec Pharmaceuticals's Gross Profit

For the Biotechnology subindustry, Fennec Pharmaceuticals's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fennec Pharmaceuticals's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fennec Pharmaceuticals's Gross Profit distribution charts can be found below:

* The bar in red indicates where Fennec Pharmaceuticals's Gross Profit falls into.



Fennec Pharmaceuticals Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Fennec Pharmaceuticals's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=28.512 - 1.689
=26.82

Fennec Pharmaceuticals's Gross Profit for the quarter that ended in Dec. 2023 is calculated as

Gross Profit (Q: Dec. 2023 )=Revenue - Cost of Goods Sold
=13.06 - 0.919
=12.14

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$26.90 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Fennec Pharmaceuticals's Gross Margin % for the quarter that ended in Dec. 2023 is calculated as

Gross Margin % (Q: Dec. 2023 )=Gross Profit (Q: Dec. 2023 ) / Revenue (Q: Dec. 2023 )
=(Revenue - Cost of Goods Sold) / Revenue
=12.14 / 13.06
=92.96 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Fennec Pharmaceuticals  (TSX:FRX) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Fennec Pharmaceuticals had a gross margin of 92.96% for the quarter that ended in Dec. 2023 => Durable competitive advantage


Fennec Pharmaceuticals Gross Profit Related Terms

Thank you for viewing the detailed overview of Fennec Pharmaceuticals's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Fennec Pharmaceuticals (TSX:FRX) Business Description

Traded in Other Exchanges
Address
68 TW Alexander Drive, PO Box 13628, Research Triangle Park, NC, USA, 27709
Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children. The company principally operates in the United States.

Fennec Pharmaceuticals (TSX:FRX) Headlines

From GuruFocus

Beachbody CEO Letter to Forest Road Shareholders

By Business Wire Business Wire 06-09-2021